Literature DB >> 17415316

Addition of basal insulin to oral antidiabetic agents: a goal-directed approach to type 2 diabetes therapy.

Louis Kuritzky1.   

Abstract

The objective of this article is to review current findings in the published literature on the efficacy of insulin therapy in combination with oral antidiabetic agents, with a focus on practical information that might help to provide an evidence-based template for selecting how best to combine oral agents and basal insulin in patients with type 2 diabetes. Here we review the current oral agents used to treat type 2 diabetes, their mechanisms of action, and how they can be combined with insulin therapy to help patients achieve guideline-recommended glycemic goals. While practical advice exists for initiating a therapeutic regimen comprised of basal insulin and oral agent(s), direction as to appropriate therapy for individual patients with differing physiologic requirements is needed. Oral antidiabetic therapy in combination with insulin provides an effective therapeutic option for patients who are unable to achieve or maintain glycemic goals on oral therapy alone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17415316      PMCID: PMC1868361     

Source DB:  PubMed          Journal:  MedGenMed        ISSN: 1531-0132


  45 in total

Review 1.  Oral antihyperglycemic therapy for type 2 diabetes: scientific review.

Authors:  Silvio E Inzucchi
Journal:  JAMA       Date:  2002-01-16       Impact factor: 56.272

Review 2.  Oral agents in the management of type 2 diabetes mellitus.

Authors:  B Luna; M N Feinglos
Journal:  Am Fam Physician       Date:  2001-05-01       Impact factor: 3.292

3.  Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

Authors:  H Yki-Järvinen; A Dressler; M Ziemen
Journal:  Diabetes Care       Date:  2000-08       Impact factor: 19.112

4.  Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).

Authors:  Alex Wright; A C Felix Burden; Richard B Paisey; Carole A Cull; Rury R Holman
Journal:  Diabetes Care       Date:  2002-02       Impact factor: 19.112

5.  Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.

Authors:  D E Kelley; P Bidot; Z Freedman; B Haag; D Podlecki; M Rendell; D Schimel; S Weiss; T Taylor; A Krol; J Magner
Journal:  Diabetes Care       Date:  1998-12       Impact factor: 19.112

6.  Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.

Authors:  J Rosenstock; S L Schwartz; C M Clark; G D Park; D W Donley; M B Edwards
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

Review 7.  Insulin glargine.

Authors:  R K Campbell; J R White; T Levien; D Baker
Journal:  Clin Ther       Date:  2001-12       Impact factor: 3.393

8.  Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.

Authors:  K Hermansen; S Madsbad; H Perrild; A Kristensen; M Axelsen
Journal:  Diabetes Care       Date:  2001-02       Impact factor: 19.112

9.  The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management--2000 update.

Authors: 
Journal:  Endocr Pract       Date:  2000 Jan-Feb       Impact factor: 3.443

10.  A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.

Authors:  P Raskin; M Rendell; M C Riddle; J F Dole; M I Freed; J Rosenstock
Journal:  Diabetes Care       Date:  2001-07       Impact factor: 19.112

View more
  2 in total

1.  Real-World Observational Study of Glimepiride and Metformin Fixed-Dose Combination Along With Insulin in the Management of Type 2 Diabetes Mellitus: Indian Experience.

Authors:  K M Prasanna Kumar; Krishna Seshadri; S R Aravind; Prasun Deb; K D Modi; Raju A Gopal; Vijaya Kumar G; Cr Anand Moses; Mahesh Abhyankar; Santosh Revenkar
Journal:  Cureus       Date:  2021-01-30

Review 2.  Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention.

Authors:  Yanling Wu; Yanping Ding; Yoshimasa Tanaka; Wen Zhang
Journal:  Int J Med Sci       Date:  2014-09-06       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.